ETIDIOH - NEW

  Overall Risk statement -- This RRA aims to assess the overall public health risk at the global level posed by the chikungunya virus (CHIKV) transmission during 2025, considering the criteria of potential risk for human health , the risk of geographical spread , and the risk of insufficient control capacities with available resources, and the implications for the 2026 transmission season .  -- Chikungunya virus (CHIKV) poses a significant and growing global health risk due to large and widespread regional outbreaks in recent years, climate-driven mosquito expansion , lack of specific treatment , and increasing international travel.  -- While mortality remains relatively low , the CHIKV infection can cause prolonged arthritis with disability as well as  severe illness in some patients.  -- From 1 January to 10 December 2025, 502 264 CHIKV disease cases including  208 335 confirmed cases, and 186 CHIKV deaths , were reported globally.  -- While certain ...

  Situation at a glance Since the beginning of 2025 and as of 21 December 2025, a total of 19 cases of Middle East respiratory syndrome coronavirus (MERS- CoV), including four deaths have been reported to WHO globally.  Of the 19 cases, 17 were reported by the Kingdom of Saudi Arabia (KSA), and two were reported from France .  Between 4 June and 21 December 2025, the Ministry of Health (MoH) of KSA reported a total of seven cases of MERS-CoV infection, including two deaths .  In addition , at the beginning of December 2025, the National IHR Focal Point (IHR NFP) for France also reported two MERS-CoV travel – associated cases ; involving individuals with recent travel to countries in the Arabian Peninsula.  The notification of these latest cases does not change the overall risk assessment , which remains moderate at both the global and regional levels .  These cases show that the virus continues to pose a threat in countries where it is circulating in dromed...

  Influenza at the human-animal interface  Summary and risk assessment, from 6 November to 19 December 2025 {1} -- New human cases {1,2}:  - From 6 November to 19 December 2025, based on reporting date , the detection of influenza A( H5N1 ) in one human , A( H5N5 ) in one human , A( H9N2 ) in seven humans , and an influenza A( H1N1 ) variant virus in one human were reported officially.  - In addition , one human case of infection with an influenza A( H1N2 ) variant virus was detected.  -- Circulation of influenza viruses with zoonotic potential in animals :  - High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3}  - The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4}  - Additionally, low pathogenicity avian influenza viruses as well a...

  {Excerpt} Since 1997, more than 1000 cases of highly pathogenic avian influenza A(H5N1) have been reported in humans . During this time, A(H5N1) viruses have evolved into dozens of clades , showing ever-expanding phylogenetic diversification and geographical spread . Over the past 5 years, clade 2.3.4.4b A(H5N1) viruses have exhibited rapid global expansion in migratory birds, with spillover to an increasing range of marine and terrestrial mammalian species . Among these species are dairy cattle , not previously recognised as a permissive host for influenza A viruses (IAV), leading to widespread clade 2.3.4.4b A(H5N1) outbreaks in herds in the USA and sporadic human infections linked with exposure to infected animals since March 2024. While person-to-person transmission has not been detected in the USA, the increased geographical distribution of and susceptibility of mammalian hosts to clade 2.3.4.4b A(H5N1) viruses has brought to the forefront a need to assess the pandemic risk ...

  Key points: -- The WHO Technical Advisory Group on COVID-19 Vaccine Composition ( TAG-CO-VAC ) held its twice-yearly decision-making meeting in December 2025 to review the evolution of SARS-CoV-2, the performance of currently approved COVID-19 vaccines and the implications for COVID-19 vaccine antigen composition. -- The objective of an update to COVID-19 vaccine antigen composition is to enhance vaccine-induced immune responses to circulating SARS-CoV-2 variants. -- Following this meeting, the TAG-CO-VAC advises vaccine manufacturers that monovalent LP.8.1 is the recommended vaccine antigen. -- The previously recommended JN.1 lineage (JN.1 or KP.2) antigens remain suitable alternatives and vaccination should not be delayed in anticipation of access to vaccines with the LP.8.1 composition. -- Other approaches that demonstrate broad and robust neutralizing antibody responses or efficacy against currently circulating SARS-CoV-2 variants could also be considered. -- Vaccination rema...